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Abstract 
Drugs whose targets have genetic evidence to support efficacy and 
safety are more likely to be approved after clinical development. In 
this paper, we provide an overview of how natural sequence variation 
in the genes that encode drug targets can be used in Mendelian 
randomization analyses to offer insight into mechanism-based 
efficacy and adverse effects. Large databases of summary level 
genetic association data are increasingly available and can be 
leveraged to identify and validate variants that serve as proxies for 
drug target perturbation. As with all empirical research, Mendelian 
randomization has limitations including genetic confounding, its 
consideration of lifelong effects, and issues related to heterogeneity 
across different tissues and populations. When appropriately applied, 
Mendelian randomization provides a useful empirical framework for 
using population level data to improve the success rates of the drug 
development pipeline.
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Introduction
The majority of small molecule and biologic drugs exert their 
effects by perturbing protein targets1. The identification of such 
targets is therefore central to drug discovery. Despite increas-
ing investment in research and development within the phar-
maceutical industry2, overall drug development failure rates 
remain high3–8, most notably for targets that represent novel 
mechanisms. Such failures result in increased costs and reduced 
availability of novel agents9.
With the recent growth in genetic data10, there has been 
substantial progress in the identification of genes that are linked 
to human health and disease. Genetic data can potentially be 
used for identifying and prioritizing novel drug targets and 
indications2. For example, genome-wide association studies 
(GWAS) have corroborated approximately 70 of the 670 known 
effects of licensed drugs through associations at the loci of 
the genes coding for their corresponding target proteins11. 
Studies of drug development programs have also shown that 
targets with genomic support have a higher rate of success2,12–15.
Mendelian randomization
Through the random allocation of genetic variants at 
conception, genetic studies in human populations can imi-
tate the design of randomized controlled trials (RCT)16,17. Such 
investigation uses genetic variants as instrumental variables for 
studying the effect of an exposure on an outcome, and has 
been referred to as Mendelian randomization (MR)18. Pheno-
typic observational studies are limited in their ability to draw 
causal inferences due to bias from confounding and reverse 
causation18. In contrast, MR uses the random allocation of 
genetic variants from parents to offspring during conception to 
guard against these biases.
MR requires the following instrumental variable assumptions: 
the genetic variant i) is associated with the exposure (relevance), 
ii) has no common cause with the outcome (independence), 
and iii) only affects the outcome via the exposure (exclusion 
restriction)19,20. The first of these is testable; the remaining 
assumptions are untestable but falsifiable. Assumption iii) the 
exclusion restriction, assumes that the genetic variant affects the 
outcome through the exposure and not any other horizontally 
pleiotropic pathways18,21. Further assumptions are also required 
to obtain valid point estimates, for instance, that the influence 
of the exposure on the outcome is the same for all individuals 
(effect homogeneity) or that the exposure is a monotonic (always 
increasing or always decreasing) function of the instrument for 
all individuals in the population (monotonicity)19. In addition, 
the interpretation of MR findings can have particular nuances, 
as previously described22.
Where the exposure under study is perturbation of a drug 
target, MR can be used to explore drug effects (Figure 1)23,24. 
Figure 1. Principles of Mendelian randomization studies (MR) studying drug effects. MR makes use of genetic variants located 
within or close to a gene encoding a drug target (e.g. at HMGCR encoding the drug target of statins) that lead to downstream effects similar 
to the desired drug response (e.g. lowering of low-density lipoprotein [LDL] cholesterol) in order to explore effects on clinical outcomes (e.g. 
risk of coronary artery disease). SNP: single-nucleotide polymorphism.
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For drug target MR specifically, genetic variants such as 
single-nucleotide polymorphisms (SNPs) related to the function 
or expression of the drug target protein can be used as instrumental 
variables to study the effect of perturbing that drug target25,26. 
These variants are typically in or near the gene that encodes the 
drug target (cis-variants). Such MR can be used in drug 
development to investigate the likely efficacy and safety of 
perturbing novel drug targets27,28, as well as explore the 
repurposing potential and adverse effects of existing drugs25.
The identification and validation of appropriate genetic vari-
ants as instrumental variables for an exposure is critical for the 
design and interpretation of all MR analyses29. While previous 
work has offered practical advice on selecting instruments for MR 
studies considering disease biomarkers24, the field is continu-
ing to evolve rapidly30. The growth in genetic association study 
data that extends to tissue-specific gene expression31, circulating 
proteins32, metabolites33,34 and cytokines35, has been coupled 
with increased efficiency of MR studies using automated soft-
ware, databases, statistical packages and readily available 
code30,36–38. However, there is still no consensus on the strat-
egy for identifying genetic instruments and exploring potential 
drug effects with MR. Here we discuss practical considerations 
while also offering illustrative examples for the most relevant 
points. We describe issues relating to selection of genetic vari-
ants as proxies for drug target perturbation, evaluation of the 
plausibility of genetic variants as proxies for drug target per-
turbation, generation and interpretation of MR estimates, and 
limitations of MR for investigating drug target perturbation. 
Finally, we offer a step-by-step framework for how to conduct a 
drug target MR study (Box 1).
Instrument selection
MR investigations of drug effects have mainly studied small 
molecule, peptide and biotherapeutic drugs39,40, where genetic 
instruments are selected as variants that mimic perturbation of 
their protein targets. Instrument selection can be considered in 
two parts: i) identifying the gene or group of genes correspond-
ing to the drug target proteins and ii) selecting genetic variants 
to proxy perturbation of the drug targets. These steps are 
discussed in detail below, followed by consideration of drugs 
that have targets made up of multiple proteins.
Identifying genes corresponding to drug target 
proteins
The key difference between conventional MR for an exposure 
and MR for the investigation of drug effects is that for the lat-
ter the instrument can be constructed in relation to the gene 
corresponding to the drug target, rather than genetic variants 
from across the genome (Table 1). The first step of this process 
is therefore to identify the drug target of interest and its corre-
sponding gene. Resources such as DrugBank (which is freely 
available for non-commercial purposes) provide information 
about existing drugs, including their mechanism of action, tar-
gets and their corresponding gene(s), and indications41. Where 
the target of a drug is known, information regarding the corre-
sponding gene can also be obtained from other databases such as 
Ensembl and UniProt42,43.
Selecting genetic variants to proxy drug targets
Several factors need to be considered when selecting genetic 
variants to proxy the effects of drug target perturbation. If MR is 
being used to investigate effects of perturbing the target of a drug 
with an existing indication, then instruments can be selected 
based on their location at the corresponding gene and associa-
tion with that indication. For instance, Gill et al. selected genetic 
variants to proxy antihypertensive drug class effects as those 
located at the gene corresponding to the drug target that also 
related to systolic blood pressure in a GWAS44. If the indication 
is not known, one possible approach is to use quantitative trait 
loci for expression of the gene encoding the drug target of inter-
est (in relevant tissues or cell contexts) as instruments for 
drug target perturbation. An important limitation of gene expres-
sion is that variants affecting gene expression may not neces-
sarily also affect protein expression, and vice versa (Figure 2)45. 
Furthermore, gene expression quantitative loci have been 
reported to account for little of the heritability of complex 
diseases46. Therefore, protein expression quantitative loci may 
make better instruments for proxying drug effects than gene 
expression data, if they are available in relevant tissues and 
contexts.
As mentioned above, selected instruments for drug target 
perturbation are often restricted to cis-acting genetic variants 
– those in or close to the gene of interest. In general, such variants 
are more likely to have effects specific to the protein of inter-
est than genetic variants that are not located within the gene 
locus (trans-acting). This point is well highlighted by the 
example of C-reactive protein, for which MR analyses inves-
tigating effects of its circulating levels produce very different 
results depending on whether the instruments are selected from 
Box 1. Step-by-step guide for conducting Mendelian 
randomization (MR) analyses of drug target perturbation
1.  Determine the drug targets of interest
2.  Identify the gene(s) encoding the relevant protein(s)
3.  Choose data source for identifying instruments
4.  Select genetic variants as instruments based on:
a.    Strength of associations with downstream effects 
of drug target perturbation
b.    Linkage disequilibrium structure
c.    Distance from gene(s) encoding the drug target
5.  Validate genetic variants for use as instruments by 
confirming that they recapitulate known on-target 
drug effects
6.  Estimate effects of drug target perturbation on 
outcome(s) of interest using MR
a.    Use appropriate method to account for linkage 
disequilibrium structure between variants
b.    Scale estimates appropriately
c.    Interpret MR as representing effects of lifelong 
drug target perturbation
7.  Investigate potential adverse effects and repurposing 
opportunity using phenome-wide association study
8.  Triangulate using other interventional, observational 
and experimental data
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Table 1. Differences between conventional Mendelian randomization (MR) and MR specifically exploring drug target 
perturbation.
Conventional MR MR investigating drug effects
Aim of the analysis To investigate the effect of an exposure on an outcome
To investigate the effect of perturbing a drug target on an 
outcome
Genomic location of 
instruments Genome-wide
Often restricted to the locus of the gene encoding the drug 
target under study
Selection of genetic 
instruments
Variants associated with the exposure under 
study
Variants associated with perturbation of the drug target under 
study
Statistical analysis
Typically uses uncorrelated variants; higher 
risk of pleiotropic effects on the outcome 
through pathways unrelated to the exposure
More frequent use of methods to account for correlation 
between instrument variants; lower risk of pleiotropic effects on 
the outcome through pathways unrelated to the drug target
Figure 2. Potential strategies for selecting genetic variants as instruments for a protein drug target. Variants within or close to 
the drug target gene might be selected on the basis of their associations with gene expression and levels of the target protein or known 
downstream functions such as effects on metabolite levels or biomarkers. Notably, variants influencing gene expression and protein levels 
do not always influence the function of the derived protein product and might not translate to downstream effects comparable to those 
achieved by the pharmacological modulation of the drug target.
the CRP locus or from throughout the genome24. Related con-
siderations include how proximal cis-variants should be to 
the corresponding gene, and whether enhancer or promoter 
regions for the gene should be counted as cis-acting47. While 
some evidence currently supports that genetic variants affecting 
gene expression typically lie within 200kB of the gene locus48, 
there is no established consensus on the issue of proximity. The 
pertinent requirement is that the variant be related to the function 
or expression of the drug target. In the past, single-region 
MR analyses have sometimes used only the top variant in the 
region as a genetic instrument28,49,50. However, this approach 
can also be suboptimal if studying a region containing variants 
that have multiple conditionally independent associations with 
the exposure. For example, genetic association studies have sug-
gested that the SHBG region encoding sex-hormone binding 
globulin (SHBG) may harbor up to nine variants indepen-
dently associated with circulating SHBG concentration51, and 
that using only the top variant may limit the statistical power of 
such MR analysis.
The degree to which variants at the same locus should be 
allowed to correlate with each other through linkage disequi-
librium (LD) while still being modelled as independent also 
warrants attention. Unaccounted correlation between the vari-
ants used can result in underestimation of the standard error of 
MR estimates, yet there is no recommended LD threshold. To 
circumvent this issue, methods are available to adjust for LD 
between genetic variants used as instruments, which may help 
confirm the robustness of the findings and maximize statistical 
power52–54.
Investigating drugs with multiple targets
Many drugs do not have a target that is encoded by a single 
gene. For example, the calcium channel blocker class of 
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antihypertensive drugs have targets that are made up of pro-
teins coded by several different genes44,55. At present there is no 
consensus on the best way to combine data from multiple genes 
corresponding to a single target into an instrument. Previous 
studies have selected genetic variants related to the individual 
genes and combined their data to investigate the effect of 
perturbing the drug target, while applying clumping to ensure 
independence as described above44,55.
Instrument evaluation
Once the instrument has been selected, it can be evaluated to 
ascertain its validity for the analysis of interest. MR analyses 
exploring drug effects can be biased if the genetic variants 
incorporated as instruments have “horizontal” pleiotropic 
effects, where there are pathways from the variant to the specific 
outcome under consideration that do not pass through the expo-
sure of interest56. In contrast, “vertical” pleiotropy lies on the 
causal pathway between the pharmacological mechanism and 
outcome56. Vertical pleiotropy does not bias MR estimates 
and is often of interest as it can provide insight into causal 
mechanisms and mediation. As with MR generally, one 
of the most useful approaches for evaluating instrument 
validity is to investigate its relation to a known effect of the 
exposure under consideration57. This approach is feasible for MR 
used to predict the effect of perturbing targets for which there 
are drugs with established indications and known associations 
with biomarkers58. For example, Walker et al. selected genetic 
variants to proxy antihypertensive drugs from gene expression 
data and validated these instruments through their associations 
with systolic blood pressure, prior to applying MR analyses 
investigating the outcome of interest, Alzheimer’s disease55. 
An instrument may also be examined in relation to potential 
confounders, in order to investigate violations of the indepen-
dence and exclusion restriction assumptions necessary for MR56. 
Berry et al. illustrated such an approach during their evalua-
tion of genetic proxies for vitamin D status59. In this study, the 
association of variants with social, dietary and lifestyle factors 
was investigated, to identify potential sources of confounding. 
Complementary data may also be used for instrument evaluation. 
For example, MR studies designed to investigate the effect of 
genetically predicted variations in interleukin-6 (IL6) signal-
ing would be expected to show that the selected instruments 
associate with molecules that are downstream of the pathway49. 
Genetic association estimates for the serum levels of several 
of these molecules are available, including IL6 and IL6 
receptor (IL6R), C-reactive protein (CRP) and fibrinogen60. 
Hence, if the selected genetic instruments are valid 
proxies for IL6 signaling, they may be expected to show 
consistent effects across these molecules. An alternative 
example is provided by Wurtz et al. who demonstrated consis-
tency between the metabolic changes associated with starting 
statins and metabolomic associations of the HMGCR variant 
rs12916 that was used to proxy statin effect61.
Analysis
Given a set of genetic instruments, the statistical methods used 
for MR investigation of drug target perturbation are similar to 
those used for MR more generally62. Interpretability is often 
facilitated by scaling of genetic associations to unit change in a 
trait related to drug target perturbation. For example, for analy-
ses considering associations of variants in the HMGCR gene 
that are used to proxy statin drug effects, estimates may be scaled 
to change in low-density lipoprotein cholesterol levels50,63–65. 
As another example, for analyses investigating IL6R signal-
ing using variants in the IL6R gene, effects may be scaled to 
downstream changes in CRP levels49,60. Care must be taken in 
the interpretation of such scaled estimates however, because 
although MR estimates may be directionally concordant to 
the effect of drug target perturbation on the biomarker, their 
magnitudes may not be comparable66.
Statistical approaches used to evaluate potential bias from 
horizontal pleiotropy in MR analyses can also be used in MR 
investigating drug target perturbation62. However, variants 
selected as instruments for drug target perturbation are often 
selected from within a specific locus rather than from through-
out the genome, and may be limited in number. Statistical 
sensitivity analyses for investigating horizontal pleiotropy typi-
cally require large numbers of genetic variants, and so may 
not be suitable for many drug target MR analyses29. Assess-
ment of heterogeneity between MR estimates produced by 
variants in a single locus is still possible however, and can 
be used to inform on potential bias related to horizontal 
pleiotropy53,67.
In an effort to better explore the target region and increase 
statistical power, genetic variants that have weaker associa-
tions with perturbation of the drug target may be considered as 
instruments27,68. Despite the potential benefits of this approach69, 
care must be taken to avoid weak instrument bias54,70. Under a 
two-sample design, weak instrument bias will attenuate MR 
estimates towards the null71.
MR can be used to assess a wide range of outcome traits and 
thus investigate potential effects of perturbing the drug target on 
these traits72. Such studies are often conducted as hypothesis-free, 
phenome-wide association analyses (PheWAS)73,74, and can 
be helpful for exploring potential adverse effects or identifying 
previously unknown re-purposing opportunities. For example, 
Schmidt et al. conducted a PheWAS of the PCSK9 locus to 
assess potential adverse effects of PCSK9 inhibitor drugs75.
In addition to using MR, it is also possible to generate genetic 
evidence supporting a causal effect of drug target perturbation 
on an outcome by identifying proportionality of genetic asso-
ciations with traits proxying drug target perturbation and the 
outcome, at the corresponding drug target gene locus. Such 
investigation is referred to as genetic colocalization, and can 
help distinguish causation from genetic confounding (such as 
may arise due to horizontal pleiotropy). Popular colocalization 
methods include coloc76, moloc77, eCAVIAR78 and HEIDI79. 
However, a limitation of many colocalization approaches is 
that they assume there is only a single causal variant at the 
considered locus.
Triangulation, the practice of integrating evidence from several 
different methodological approaches and data sources that each 
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differ in their susceptibility to bias, is another important 
aspect of interpreting the analysis80. MR evidence should be 
considered alongside other study designs to increase confidence 
in findings58. For example, the European Atherosclerosis Soci-
ety consensus statement on the role of low-density lipoproteins 
on atherosclerotic cardiovascular disease considers evidence 
from inherited disorders of lipid metabolism, prospective 
epidemiologic studies, MR investigations and RCTs81. 
Moreover, comparing instruments between different MR studies 
of the same exposure can provide additional evidence. For 
example, both Gill et al. and Walker et al. independently derived 
instruments for antihypertensive drug effects that perform 
comparably when tested against a common outcome44,55. Although 
different MR studies may use similar or overlapping data 
sources, different instrument selection approaches can make 
analyses vulnerable to distinct biases and so also have a role 
in triangulation of evidence.
Limitations
As with all research methods, MR has limitations82. RCTs 
remain the best source of evidence evaluating drug efficacy and 
guiding clinical practice83. While MR and RCTs have the same 
aim – reliable evidence of causation – they estimate different 
treatment parameters, which are not directly comparable. Genetic 
variants typically have smaller effects which accumulate across 
the entire life-course, whereas pharmacological agents are 
often prescribed later in life and typically have larger effects. 
Therefore, MR estimates reflect the lifelong effects of perturb-
ing a drug target, which may not be equivalent to interventions 
given at a specific point in time and for a shorter time period 
(Figure 3). While these differences make it unlikely that MR 
estimates will accurately reflect the size of effect of a phar-
macological intervention, they are still a useful indication of 
presence and direction of causal effects58.
A further limitation of MR for studying the effects of 
drug target perturbation is that it may not account for 
post-transcriptional and post-translational modification in the 
pathway from a gene to a biologically functional protein. 
Well-conducted MR analyses may be able to inform broadly 
on drug class effects, but not necessarily provide information 
on the effects of a specific pharmacological agent. For 
Figure 3. Comparison between Mendelian randomization (MR) study for drug effects and randomized clinical trial (RCT). Similar 
to the randomization process of RCTs, the random allocation of alleles at a drug target gene in MR studies allows the distribution of 
individuals to groups that differ only regarding the downstream effects of the drug target and not other confounders. While the random 
allocation of alleles in MR studies happens at conception and leads to lifelong effects, the randomization in RCTs typically happens later in 
life and focuses on the effects of short-term interventions.
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example, dihydropyridine and non-dihydropyridine subclasses of 
calcium-channel blocker antihypertensive drugs have distinct 
pharmacological effects. Genetic variants that affect blood pres-
sure via calcium-channel blockade can estimate the effects of 
calcium-channel targeting drugs in general, but cannot differentiate 
the relative effects of dihydropyridine versus non-dihydropyridine 
subclasses44. Furthermore, MR in this context is applied to drug 
targets and not compounds – so it can be used to investigate the 
effects of perturbing a drug target, but is unlikely to be able to 
offer insight towards molecule specific effects28.
Drug effects also vary in different tissues and populations, and 
similarly MR estimates for the effects of perturbing drug 
targets may only be valid if genetic association data from the 
relevant tissues or populations are used. This limitation can have 
implications for both identifying instruments and using MR 
to study drug effects, as highlighted in an example that used 
gene expression data to identify instruments for antihyperten-
sive drug classes in the investigation of repurposing potential for 
the prevention of Alzheimer’s disease55. Here, it is not clear 
whether the same genetic variants related to gene expression in 
vascular, cardiac and brain tissue. Furthermore, to date, most 
genotyped samples have been sampled from European ances-
try populations. While this approach minimizes the risk of 
population stratification and false-positive GWAS signals, 
consideration of distinct ancestral groups is likely to offer 
novel insight. For example, genetic evidence on the effects 
of alcohol comes from variants in the ALDH2 gene, which 
are common in Asian, but not European populations84.
Conclusion
Over the last decade, MR has become a widely used epide-
miological tool for estimating the causal effects of risk factors 
on clinical outcomes. On top of this well-studied applica-
tion, there are now multiple examples highlighting its power for 
investigating drug effects. Despite its explicit assumptions, 
modern developments in statistical methodology and the 
widespread availability of multiple levels of omics data 
have provided the necessary resources to more reliably and 
efficiently use MR in order to study drug effects. As such, it 
has found a growing niche within the broader framework for 
exploring therapeutic targets, efficacy, adverse effects and 
repurposing potential. Given the high failure rates of clini-
cal trials and that drug targets with genetic support are more 
likely to make it through the development pipeline13,15,23, MR 
can provide evidence for prioritizing agents to move forward in 
development.
Data availability
No data is associated with this article.
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risk factors for many diseases, and whose further use in identifying drug targets is immensely 
valuable. This is a helpful guide to using Mendelian randomization (MR) to investigate drug targets 
but needs to address some additional relevant issues that could confuse researchers. 
 
Key points that need to be made clearer:
MR does not quite imitate a randomized controlled trial (RCT). RCTs randomize to the drug 
or intervention after recruitment, meaning well-conducted RCTs are not open to 
confounding (bias typically from common causes of intervention/exposure and outcome) or 
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conception. As such, MR studies usually only concern survivors of their genetic make-up and 
also of the disease of interest, i.e., they may be selected on genetic variants and the disease 
of interest, meaning they are open to selection bias. In this situation estimates for the drug 
target on the disease of interest might be attenuated, reversed, or spurious. In addition, 
inadvertently selecting survivors of their genetic variants and competing risk of the disease 
of interest will similarly affect the estimate for the drug target on the disease of interest, 
even if nobody has died of the disease of interest before recruitment. Examples of this issue 
include the genetic variants corresponding to PCSK9 inhibitors appearing to have no effect 
on stroke1 and the genetic variant corresponding to statins, i.e., rs12916, appearing to have 
no effect on stroke.2 These findings conflict with RCTs, and are likely the result of selection 
bias, as described above. 
 
Unlike RCTs, MR is best suited for investigations of the effects of drugs intended to reduce 
the risk of disease but is not necessarily suitable for studies of drug effects in patients. An 
MR study of a disease treatment drug in patients would be open to selection bias because 
patients are typically survivors of their genetic make-up and of the disease of interest. This 
point has been explained in relation to genetic studies,3 and solutions are under-
development for both genetic studies and MR. Researchers often want to use MR to assess 
effects of drugs in a patient sample just as they can in an RCT, so it needs to be explained 
when such an MR study would and would not be likely to give valid results. 
 
2. 
Criteria for suitable samples for selecting genetic instruments for a drug need to be given. 
For example, should the sample be population-representative, in young people, from a trial 
of the relevant drug, from controls only of a case-control study?
3. 
 
There are also some other points that need clarification.
Paragraph 3, The major sources of bias in phenotypic observational studies are now 
understood to be confounding and selection bias, as explained here.4,5 So, selection bias 
needs to be added to the second to last sentence of this paragraph. The last sentence of the 
same paragraph then needs to be amended slightly, because MR is open to selection bias, 
as explained above. 
 
1. 
Paragraph 4, the elaboration of the exclusion restriction should explain what “horizontal 
pleiotropy” is because it has not been mentioned before. Please also make it clear that this 
assumption is violated if any open path from genetic variant to outcome exists that does 




In the Limitations section, or elsewhere, please explain the differences between an RCT and 
an MR study in terms of selection bias and types of questions that can be answered by each 
design. Ensure Figure 3 reflects these differences.
3. 
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Review of the manuscript (Gill et al., 2021) 
 
This is a clearly written paper concerning the use of genetics to infer drug’s effects on health 
outcomes. The paper summarises landmark studies/commentaries in this area of research and 
have covered the majority of the points. I have some comments for the authors’ consideration. 
 
Major comments
Although the use of genetics to infer effect of medication is promising, one of the 
challenges is the identification of a relevant variant to mimic medication use. Previous 
papers mainly use postulated phenotypes to identify the relevant causal variant (e.g. LDL 
cholesterol for HMGCR or systolic blood pressure for genetic targets of anti-hypertensives). 
However, the choice may not be that clear for other medications. For example, researchers 
may choose HbA1c over fasting glucose (PMID: 32748028)1 to identify variants related to 
metformin because of sample size consideration and genotype coverage in the phenotype 
datasets (as per MAGIC database). Similarly, there may be pleiotropic effects of medication 
that are not mediated via the proposed phenotypes used to select the variants in Mendelian 
randomization and hence may not be able to capture the total effect of the medications. I 
think these are challenges that would be worth discussing to stimulate additional research. 
The use of proteomic data may help solve the abovementioned problem although 




Can the authors also comment on other approaches such as factorial MR design to 
investigate combined effects of medications (PMID: 27959767)?2 
 
○
Although Mendelian randomization studies are less vulnerable to confounding than 
observational studies, selection bias could still be an issue, in particular when this method is 








I am not sure if sensitivity analyses for correlated variants perform as well as uncorrelated 
variants. For example, a previous study commented that although MR-Egger can be 





Figure 3: I think it should be randomized controlled trial for RCT. 
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Firstly, I thank the Wellcome Open Research editorial team for the opportunity to provide 
feedback on the review by Gill et al. (2021), entitled “Mendelian randomization for studying the 
effects of perturbing drug targets”. I have reviewed this work in detail in concert with Pedrum 
Mohammadi-Shemirani and the subsequent comments reflect our joint assessment. Gill et al. 
reviewed an increasingly popular application of Mendelian Randomization analyses to understand 
causal on-target effects of drug targets on disease risk. Current practices, considerations, and 
limitations of this approach were thoroughly summarized and thus we only provide minor 
comments. Firstly, while Figure 1 is a useful illustration, the last panel may be misinterpreted as 
decreasing LDL is associated with a greater risk of CAD. As such, Figure 1 should be amended for 
clarity. Secondly, as authors correctly acknowledge, restricting instruments to cis variation is the 
standard practice to mitigate the potential for genetic confounding, but it should also be noted 
that this still leaves open the possibility for genetic confounding, particularly in regions containing 
multiple protein-coding genes. Multivariable MR conditioning for the effects of the genetic 
instruments on the surrounding gene products may represent a way to assess whether findings 
may be confounded by proximal gene products when such data is available, an approach 
implemented by Porcu et al. (2019) (https://www.nature.com/articles/s41467-019-10936-0).1 
Similarly, in the section titled “Selecting genetic variants to proxy drug targets”, a qualifying 
statement may be warranted regarding the selection of genetic variants based on association with 
known indications. If pQTL data is available, this approach may better serve instrument validation 
while a selection of variants is supported by evidence of association with protein expression or 
function. If no such data is available, evidence of association with known indications can be used, 
but it warrants a cautious approach with careful consideration of the cis window and other 
protein-coding genes therein. Thirdly, authors should further comment on the careful use of 
trans-instruments to approximate drug targets as was executed by Georgakis et al. (2019) 
https://pubmed.ncbi.nlm.nih.gov/30586705/.2 Fourth, we appreciate the authors’ decision to 
include example resources and databases to guide instrument selection (e.g., Ensembl, DrugBank, 
etc.), particularly for novice readers. Would the authors be able to provide similar suggested 
resources for other sections? For instance, databases to identify promoter and enhancer regions 
(e.g., GeneCards), or tools to help investigate violations of the independence and exclusion 
restriction assumptions (e.g., PhenoScanner). Lastly, we believe the following statement illustrates 
a very important point: “Moreover, comparing instruments between different MR studies of the same 
exposure can provide additional evidence. For example, both Gill et al. and Walker et al. independently 
derived instruments for antihypertensive drug effects that perform comparably when tested against a 
common outcome44,55 Although different MR studies may use similar or overlapping data sources, 
different instrument selection approaches can make analyses vulnerable to distinct biases and so also 
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have a role in triangulation of evidence.” Perhaps this should be briefly commented on in the 
context of technological biases between different proteomics and metabolomic technologies (for 
example https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277005/)3 thus further emphasizing the 
importance of ensuring the robustness of MR results using alternative instruments. As proteome-
wide pQTL data becomes increasingly available to the public, such sensitivity analyses should 
become more commonplace. Overall, this review is exquisitely written, thoughtful, and 
appropriately referenced. Accordingly, we have no major concerns and only offer the 
aforementioned minor comments. 
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